Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT